CXA 10

Drug Profile

CXA 10

Alternative Names: CXA-10

Latest Information Update: 16 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Complexa
  • Class Nitro compounds; Oleic acids; Small molecules; Unsaturated fatty acids; Urologics
  • Mechanism of Action NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute kidney injury; Renal failure

Most Recent Events

  • 26 Jul 2017 Complexa plans a phase II trial for Focal segmental glomerulosclerosis in early 2018
  • 16 May 2016 Chemical information added
  • 12 Nov 2015 Complexa completes four phase I trials (NCT02127190, NCT02248051, NCT02460146, NCT02313064) in Acute kidney injury in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top